Axsome Therapeutics
AXSM
190 hedge funds and large institutions have $1.99B invested in Axsome Therapeutics in 2020 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 68 increasing their positions, 48 reducing their positions, and 27 closing their positions.
104% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 27
48% more capital invested
Capital invested by funds: $1.34B → $1.99B (+$648M)
42% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 48
17% more funds holding
Funds holding: 163 → 190 (+27)
3.8% more ownership
Funds ownership: 61.61% → 65.41% (+3.8%)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
25% less call options, than puts
Call options by funds: $51.7M | Put options by funds: $69M
Top Buyers
| 1 |
RI
RTW Investments
New York
|
+$46.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.5M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$40.1M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$26.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.1M |
Top Sellers
| 1 |
VA
VR Adviser
New York
|
-$47.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$32.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$23.6M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$20.4M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$16.8M |
AXSM Hedge Fund Activity: Q2 2020 in Review
190 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q2 2020, worth a combined $1.99B — up 48% from $1.34B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new AXSM positions and 27 closed out — a net gain of 28 holders — while 68 added to existing stakes and 48 trimmed.
The largest buyer was RTW Investments, adding an estimated $46.6M. The largest seller was VR Adviser, exiting entirely with an estimated $47.7M sold.
- 190 institutional investors held Axsome Therapeutics (AXSM) as of Q2 2020, up from 163 in Q1 2020.
- Funds reported $1.99B of Axsome Therapeutics stock for Q2 2020, up 48% quarter-over-quarter.
- 55 funds opened new Axsome Therapeutics positions in Q2 2020 and 27 closed out, a net change of +28 holders.
- The largest Axsome Therapeutics buyer in Q2 2020 was RTW Investments, an estimated $46.6M added.
- The largest Axsome Therapeutics seller in Q2 2020 was VR Adviser, an estimated $47.7M sold.
Based on aggregated 13F filings for Q2 2020.